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Abstract
Objective: Curative surgery is not an option for many patients with clinical stage I non-small-cell
lung carcinoma (NSCLC), but radical radiosurgery may be effective.
Methods: Inoperable patients with small peripheral clinical stage I NSCLC were enrolled in this
study. Three-to-five fiducial markers were implanted in or near tumors under CT guidance. Gross
tumor volumes (GTVs) were contoured using lung windows. The GTV margin was expanded by 5
mm to establish the planning treatment volume (PTV). A dose of 42–60 Gy was delivered to the
PTV in 3 equal fractions in less than 2 weeks using the CyberKnife radiosurgery system. The 30-Gy
isodose contour extended at least 1 cm from the GTV. Physical examination, CT imaging and
pulmonary function testing were completed at 6 months intervals for three years following
treatment.
Results: Twenty patients with an average maximum tumor diameter of 2.2 cm (range, 1.1 – 3.5
cm) and a mean FEV1 of 1.08 liters (range, 0.53 – 1.71 L) were treated. Pneumothorax requiring
tube thoracostomy occurred following CT-guided fiducial placement in 25% of the patients. All
patients completed treatment with few acute side effects and no procedure-related mortality.
Transient chest wall discomfort developed in 8 of the 12 patients with lesions within 5 mm of the
pleura. The mean percentage of the total lung volume receiving a minimum of 15 Gy was 7.3%
(range, 2.4% to 11.3%). One patient who received concurrent gefitinib developed short-lived, grade
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III radiation pneumonitis. The mean percent predicted DLCO decreased by 9% and 11% at 6 and
12 months, respectively. There were no local failures, regional lymph node recurrences or distant
metastases. With a median follow-up of 25 months for the surviving patients, Kaplan-Meier overall
survival estimate at 2 years was 87%, with deaths due to COPD progression.
Conclusion: Radical CyberKnife radiosurgery is a well-tolerated treatment option for inoperable
patients with small, peripheral stage I NSCLC. Effective doses and adequate margins are likely to
have contributed to the optimal early local control seen in this study.
Background
Standard therapy for operable clinical stage I non-small
cell lung cancer (NSCLC) is lobectomy, a radical surgery
requiring complete removal of the involved lobe plus ipsi-
lateral hilar and mediastinal lymph node dissection.[1]
Tumor recurrence is infrequent following lobectomy and
limited to the regional lymph nodes or distant sites. How-
ever, despite recent improvements,[2] lobectomy remains
a major operation associated with early mortality,[3] a
decline in pulmonary function[1] and multiple postoper-
ative morbidities.[4] Recently, sublobar resection with
adequate margins (> 1 cm) has been advocated for mar-
ginally operable patients with small peripheral lesions.[5]
Such treatment in appropriately selected patients provides
excellent local control without the early mortality and sig-
nificant decline in lung function associated with lobec-
tomy.
Treatment options for patients with clinical stage I NSCLC
who are not surgical candidates are limited. Inferior out-
comes with conventionally fractionated radiation
approaches have been largely attributed to poor local
tumor control.[6] secondary to historically necessary pro-
longed treatment courses, which diminish the effective-
ness of the therapy.[7,8] The development of the
stereotactic body frame with abdominal compression to
dampen respiratory lung motion has allowed for the treat-
ment of small mobile peripheral lesions with compara-
tively tight margins (1 cm) on the gross tumor.[9]
Recently completed trials suggest that extremely high bio-
logically effective doses may be delivered safely and rap-
idly to small peripheral lung tumors with this enhanced
accuracy. [10-12] As anticipated, such treatment has
resulted in improved early local control rates.[13]
We began treating small peripheral lung tumors in mid-
2004 using the CyberKnife® frameless robotic radiosur-
gery system (Accuray Incorporated, Sunnyvale, CA) with
Synchrony® respiratory motion tracking.[14,15] The accu-
racy and flexibility of the system allowed us to deliver
dose distributions capable of eradicating both the gross
tumor and the microscopic disease radiating from
it.[16,17] The goal was similar to that of sublobar resec-
tion, i.e., to eliminate the tumor with 1 cm or greater mar-
gins, and thus the approach was designated radical
radiosurgery.[14] We report preliminary outcomes from
20 consecutive inoperable patients with small, peripheral,
clinical stage I NSCLC treated using this novel treatment
approach.
Materials and methods
Eligibility
The Georgetown University Hospital institutional review
board approved this study and all participants provided
informed written consent. The multidisciplinary thoracic
oncology team evaluated patients. Prior to treatment, CT
imaging of the chest, abdomen and pelvis with IV con-
trast, PET imaging, and routine pulmonary function tests
(PFTs) were completed. Inoperable patients with patho-
logically confirmed small, peripheral, clinical Stage I
NSCLC were treated. Inoperability was defined as a post-
operative predicted forced expiratory volume in one sec-
ond (FEV1) of less than 40%, post-operative predicted
carbon monoxide diffusing capacity (DLCO) of less than
40%, VO2 max less than 10 ml/kg/min, or severe comor-
bid medical conditions.[18] Tumors were considered
small if the maximum diameter and gross volume meas-
ured less than 4 cm and 30 cc, respectively. Tumors were
considered peripheral if radical treatment was feasible
without exceeding predetermined critical central structure
maximum point dose limits (Table 1).
Fiducial Placement
With conscious sedation and local anesthesia, 3 to 5 gold
fiducials measuring 0.8–1 mm in diameter by 3–7 mm in
length (Item 351-1 Best Medical International, Inc.,
Springfield, VA) were placed with adequate spacing (1–2
cm) in or near tumors under CT-guidance as previously
described.[19,20]
Treatment Planning
Fine-cut (1.25-mm) treatment planning CTs were
obtained 7–10 days after fiducial placement during a full
inhalation breath-hold. Gross tumor volumes (GTV) were
contoured utilizing lung windows. The GTV margin was
expanded 5 mm to establish the planning treatment vol-
ume (PTV). All critical central thoracic structures (Table 1)
and the lungs were contoured to ensure that incidental
radiation delivered to these structures was limited. A treat-
ment plan was generated using the CyberKnife non-iso-Journal of Hematology & Oncology 2009, 2:1 http://www.jhoonline.org/content/2/1/1
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centric, inverse-planning algorithm with tissue density
heterogeneity corrections for lung. No attempt was made
to treat at-risk but clinically negative lymph nodes (elec-
tive nodal irradiation). In general, lower doses within the
radical range of 42 to 60 Gy in 3 fractions were prescribed
when concerns about adjacent critical structures arose and
when patients were felt to have severe pulmonary dys-
function. The radiation was delivered to an isodose line
that covered at least 95% of the PTV and resulted in the
30-Gy isodose contour extending a minimum of 1 cm
from the GTV. The percentage of the total lung volume
receiving 15 Gy or more (V15) was limited to 15%.
Finally, treatments were designed to be deliverable in 2
hours or less.
Treatment Delivery
Patients were treated according to the Georgetown Uni-
versity Hospital small peripheral pulmonary nodule pro-
tocol as previously described.[14] Briefly, pretreatment
fluoroscopy confirmed that fiducial motion correlated
with tumor motion. Subsequently, patients were brought
to the CyberKnife suite and laid supine on the treatment
table with their arms at their side. Three red light-emitting
diodes (LEDs) were placed on the patient's anterior torso
directed toward the camera array. Fiducials were located
using the orthogonal x-ray imagers. A correlation model
was created between the LEDs tracked continuously by the
camera array and the fiducial positions imaged periodi-
cally by the x-ray targeting system. During treatment deliv-
ery the tumor position was tracked using the live camera
array signal and correlation model; the linear accelerator
was moved by the robotic arm to maintain precise align-
ment with the tumor throughout the respiratory cycle.
Fiducials were imaged prior to the delivery of every third
beam to verify targeting accuracy and to update the corre-
lation model.
Follow-up Studies
Physical examination, CT imaging and routine PFTs were
performed at 6-month intervals. Complete response was
defined as resolution of the tumor on CT imaging and
partial response as a decrease in the tumor volume relative
to the treatment planning CT. Local tumor and regional
lymph node recurrence was defined as unequivocal pro-
gression on serial CT imaging. Biopsy was required to con-
firm recurrence. Toxicity was scored according to the
National Cancer Institute Common Terminology Criteria
for Adverse Events, Version 3.0.[21]
Statistical Analysis
The follow-up duration was defined as the time from the
date of completion of CyberKnife treatment to the last
date of follow-up or the date of death. Actuarial survival
and local control were calculated using the Kaplan-Meier
method. Two-sided Wilcoxon signed-rank tests were used
to assess the statistical significance of changes in pulmo-
nary function tests following radiosurgery; which were
determined using an alpha level of 0.05. Post CyberKnife
treatment changes in percent predicted FEV1, DLCO and
total lung capacity (TLC) were evaluated at 6, 12, 18 and
24 months.
Results
Patient and Tumor Characteristics
Twenty consecutive patients (5 men and 15 women) with
inoperable clinical stage I NSCLC (adenocarcinoma 10,
NSCLC not otherwise specified 7 and squamous cell car-
cinoma 3) and an Eastern Cooperative Oncology Group
(ECOG) performance status of 2 or less were treated over
a 30-month period extending from October 2004 to April
2007 (Table 2). The median follow-up time among survi-
vors was 25 months (range, 6–36 months). No patients
were lost to follow-up. All patients were heavy smokers,
80% of whom had stopped smoking in the distant past (>
3 years). Two patients chose to continue smoking despite
being diagnosed with lung cancer. Pulmonary dysfunc-
tion was the primary rationale for non-surgical treatment
and 5 patients required supplemental oxygen prior to
enrollment. Three patients were denied surgical treatment
based solely on cardiac insufficiency. Sixty percent of the
Table 1: Central Critical Structure Radiation Dose Limits
Adjacent Structure Maximum Dose Limit (total for 3 fractions)
Spinal cord 18 Gy
Left ventricle 18 Gy
Esophagus 24 Gy
Main bronchus 30 Gy
Trachea 30 Gy
Aorta 40 GyJournal of Hematology & Oncology 2009, 2:1 http://www.jhoonline.org/content/2/1/1
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lesions involved the upper and middle lobes. The mean
maximum tumor diameter was 2.2 cm (range, 1.1 – 3.5
cm) and the mean GTV was 9.7 cc (range, 1.3 – 24.4 cc).
Treatment Characteristics
Treatment plans were composed of hundreds of pencil
beams shaped using a single 20, 25, 30 or 35-mm diame-
ter circular collimator (Table 3). An average of 53 Gy was
delivered to the prescription isodose line in three 1–2
hour treatments over a 5 to 11 day period (mean, 7 days).
The percentage of the total lung volume receiving 15 Gy
or more was low (range, 2.8 – 11.3%) despite the radical
treatment intent. On average, 53 paired orthogonal x-ray
images of the fiducials were taken during each treatment
to confirm the accuracy of the correlation model. Two
patients received concurrent systemic therapy as pre-
scribed by their treating oncologists. One of these patients
completed treatment flanked by cycles 2 and 3 of full-dose
carboplatin and docetaxel. The second patient received
concurrent gefitinib.
Complications
Pneumothorax requiring tube thoracostomy developed in
25% of patients following fiducial placement. Subse-
quently, all patients completed treatment without inter-
ruption or noteworthy side effects. Following treatment,
acute toxicity consisting of mild transient fatigue was
reported in the majority of patients. Chest wall discom-
fort, typically lasting several weeks, developed in 8 of 12
patients with tumors in close proximity to the pleura (5
mm). Classic acute grade III radiation pneumonitis was
observed in 1 patient who had received 60 Gy with con-
current gefitinib treatment. Despite her relatively good
lung function (FEV1 = 1.51 L), small GTV (7.56 cc) and
low V15 (9.5% of total lung volume), she developed an
infiltrate corresponding with the high dose treatment vol-
ume and hypoxia requiring supplemental oxygen 4 weeks
following CyberKnife treatment. Her acute symptoms
appeared unrelated to her severe underlying heart disease
and resolved with steroids. She discontinued gefitinib and
is well two years following treatment.
Post-treatment Pulmonary Status
Among the entire group, no statistically significant change
was seen in percent predicted FEV1 and TLC at 6, 12, 18
or 24 months. Statistically significant reductions of 9%
(from 57% to 48%; p = 0.005) and 11% (from 57% to
46%; p = 0.05) in the mean percent predicted DLCO were
seen at 6 and 12 months, respectively. Reductions in
DLCO at 18 and 24 months did not reach statistical signif-
icance.
Table 2: Patient and Tumor Characteristics
Mean (Range)
Age (years) 74 (64 – 86)
Weight (lbs) 156 (116 – 225)
FEV1 (L) 1.08 (0.53 – 1.71)
% predicted FEV1 52 (21 – 84)
% predicted TLC 103 (69 – 136)
% predicted DLCO 57 (44 – 83)
Maximum Tumor Diameter (cm) 2.2 (1.1 – 3.5)
Gross Tumor Volume (cc) 9.7 (1.3 – 24.4)
Table 3: Treatment Characteristics
Mean (Range)
Prescribed Dose (Gy) 53 (42 – 60)
Biologic Effective Tumor Dose (BED Gy10) 147 (100–180)
Prescription Isodose Line (%) 81 (75 – 85)
Planning treatment volume coverage (%) 99 (95 – 100)
Number of beams per fraction 156 (79 – 242)
Number of paired x-ray verification images per fraction 52 (26 – 81)
Beam-on time (minutes) 73 (54–124)
Treatment course (days) 7 (5–11)
% Total lung volume receiving 15 Gy or more 7.3 (2.8–11.3)Journal of Hematology & Oncology 2009, 2:1 http://www.jhoonline.org/content/2/1/1
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CT Tumor Response
Six-month CT scans were available for all 20 patients.
Thirteen lesions responded to treatment as documented
by a decrease in tumor volume. Seven lesions were
obscured by radiation fibrosis at 6 months. At 12 months,
16 patients' CT scans were available for review. Eight
lesions continued to respond to treatment, three of which
had resolved completely. Eight lesions were obscured by
radiation fibrosis at 12 months. At 18 months, 12
patients' CT scans were available for review. Two lesions
responded completely, 2 exhibited a partial response to
treatment with only minimal residual soft tissue abnor-
mality remaining, and 8 were completely obscured by
radiation fibrosis. In each case fibrosis corresponded with
the planned high-dose treatment volume and uniformly
encompassed the fiducials (Figure 1). There were no
major changes in tumor response following the 18 month
evaluation (Table 4). Serial imaging characteristics sug-
gesting local failure were not observed during early fol-
low-up and consequently no confirmatory biopsies have
been completed.
Disease Spread and Survival
No regional lymph node failures or distant metastases
were observed during early follow-up. However, two oxy-
gen-dependent patients with pre-treatment FEV1 values of
0.53 and 0.76 liters died of progressive lung dysfunction
at 9 and 18 months, respectively. Therefore, with a
median follow-up of 25 months for surviving patients,
Kaplan-Meier overall survival at 2 years was 87% (Figure
2).
Discussion
Stage I NSCLC is curable.[22] Peripheral lung tumors are
more likely to be cured with radiosurgery than central can-
cers because there is less untreated lymphatic spread[23]
and a more favorable therapeutic window.[11] However,
consistently curing these patients without surgery will
require adequate gross tumor doses with finely tailored
dose gradients capable of eradicating known relatively
radiation-sensitive microscopic tumor extensions, while
adequately preserving lung function.
In late 2004, we initiated a radical CyberKnife protocol for
medically inoperable patients with small, peripheral,
stage I NSCLC. Ultimately, we treated a select group of
patients with relatively good performance status and
small tumor volumes because we were concerned about
CT-guided fiducial placement and treatment-related pul-
monary toxicity. Mandatory minimum gross (42 Gy)[24]
and microscopic tumor doses (30 Gy) [25-27] were
derived from historical clinical data. Continuous tracking
of respiratory tumor motion and highly accurate beam
alignment throughout treatment with the CyberKnife
allowed us to deliver radical dose distributions with
tighter margins on the GTV than historically feasible (5
mm).[14] Numerous pencil beams were used to produce
dose gradients that conform closely to the shape of the tar-
get, resulting in theoretically adequate microscopic dis-
ease doses extending an ample 1 cm or more from the
tumor.[28] Twenty patients have been treated in 30
months. With a median follow-up of 25 months for sur-
viving patients, the 2-year Kaplan-Meier local control rate
was 100%, the 2-year Kaplan-Meier overall survival rate
was 87%, and there have been no severe (grade IV) treat-
ment-related complications or early mortalities. Further-
more, despite the comprehensive nature of the treatment,
the decrement in lung function remained at acceptable
levels. Thus, we conclude that radical radiosurgery with
real-time tumor motion tracking using the CyberKnife is a
safe and effective treatment option for small peripheral
Stage I NSCLC.
Despite promising preliminary results, critical issues con-
cerning the evaluation of treatment efficacy and selection
of patients merit additional consideration. Radiosurgery
delivered to small peripheral tumors with margins ade-
quate to treat radial microscopic extension (> 1 cm) will
Right upper lobe clinical stage IA NSCLC treatment planning  CT (A), planned radiation dose distribution (B: the planning  treatment volume is shown in red and the 30 Gy isodose line  in blue), and CT at 3 and 6 months post-treatment (C and D)  show an initial decrease in the tumor volume followed by  radiation fibrosis which correlates with the planned dose dis- tribution, engulfs the fiducials and impedes evaluation of  tumor response Figure 1
Right upper lobe clinical stage IA NSCLC treatment 
planning CT (A), planned radiation dose distribution 
(B: the planning treatment volume is shown in red 
and the 30 Gy isodose line in blue), and CT at 3 and 6 
months post-treatment (C and D) show an initial 
decrease in the tumor volume followed by radiation 
fibrosis which correlates with the planned dose distri-
bution, engulfs the fiducials and impedes evaluation 
of tumor response.Journal of Hematology & Oncology 2009, 2:1 http://www.jhoonline.org/content/2/1/1
Page 6 of 9
(page number not for citation purposes)
damage peritumoral lung tissue. The acute lung injury will
often result in asymptomatic focal lung parenchyma
fibrosis corresponding with the high-dose radiation vol-
ume. [29-32] In the present study all tumors initially
responded to treatment with a decrease in volume on CT.
However, by the six-month mandatory evaluation, all
patients had developed CT evidence of peritumoral radia-
tion fibrosis. At 18 months, two thirds of the tumors were
obscured by such fibrosis, making CT tumor assessment
difficult. Preliminary analysis of PET imaging suggests
that it too is unreliable following radiosurgery.[33]
Although this trial did not require PET/CT imaging, it was
routinely completed. Moderate PET activity was often
observed following treatment, but could uniformly be
attributed to radiation fibrosis rather than tumor progres-
sion on serial imaging. Until a dependable noninvasive
means to identify early local recurrence in the presence of
fibrosis is developed, inoperable patients with fibrosis
will require close follow-up which may include
biopsy.[31]
In late 2003, Timmerman et al. published preliminary
results of the Indiana University inoperable stage I NSCLC
SBRT dose escalation trial.[12] The primary finding of this
study was that 60 Gy in 3 fractions could be safely deliv-
ered to inoperable stage I NSCLC patients in less than 2
weeks if relatively tight gross tumor margins (1 cm) were
used. However, prior to proceeding with phase II studies,
maturing data suggested that critical central thoracic struc-
tures tolerated high-dose hypofractionated radiation
poorly. Accordingly, the Radiation Therapy Oncology
Group (RTOG) protocol 0236 was limited to small (< 5
cm) tumors that lay outside the central bronchial tree, a
large area that extends 2 cm from the major airways.[11]
We chose to deliver a range of radical doses (42–60 Gy) to
smaller tumors (< 4 cm) with tighter margins (5 mm)
than RTOG 0236. Therefore, we felt confident selecting a
more inclusive definition of peripheral tumor as those
tumors located a sufficient distance from sensitive critical
central thoracic structures so that radical radiation doses
could be delivered to the PTV while adhering to maxi-
mum point dose limits (Table 1). To date, with sufficient
follow-up to detect late radiation toxicity, clinically appar-
ent radiation damage to critical central structures has not
been observed despite our delivery of a mean dose of 53
Gy to the PTV.
Peripheral thoracic structures such as the lung paren-
chyma and the chest wall did sustain clinically apparent
damage as anticipated. Despite the radical treatment
intent, the mean percentage of the total lung volume
receiving a minimum of 15 Gy was only 7.3% (range,
2.4% to 11.3%). Nonetheless, acute Grade III radiation
pneumonitis occurred in a single patient treated with con-
current gefitinib, an alleged potentiator of radiation-
induced lung fibrosis.[34] Although it is tempting to fur-
ther limit the percentage of lung receiving greater than 15
Gy in an attempt to decrease the risk of radiation pneumo-
nitis, this should only be considered if the radical treat-
ment intent is maintained.
All evaluated patients were heavy smokers, 80% of whom
had stopped smoking in the distant past (> 3 years).
Therefore, although the baseline pulmonary function was
poor, PFTs just prior to and following the treatment were
largely unaffected by recent smoking. The treatment did
not adversely affect FEV1 or TLC; however, it did cause sig-
nificant early reductions in the mean percent predicted
Table 4: Tumor response per CT imaging
6 months (%) 12 months (%) 18 Months (%)
Complete Response 0 19 17
Partial Response 65 31 17
Obscured by Fibrosis 35 50 66
Kaplan-Meier plot of overall survival Figure 2
Kaplan-Meier plot of overall survival.Journal of Hematology & Oncology 2009, 2:1 http://www.jhoonline.org/content/2/1/1
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DLCO. Predictably, the magnitude of this decline was
small, as it was in a recently reported segmentectomy
series.[35] Regrettably, 2 patients with severe COPD, who
required continuous supplemental oxygen prior to treat-
ment, died 9 and 18 months after radiosurgery secondary
to progressive pulmonary dysfunction. It is unknown
whether their deaths were premature and attributable to
treatment. Nonetheless, it is possible that a population of
inoperable stage I NSCLC patients exists, possibly those
whom are oxygen dependent, who may not benefit from
radical treatment. Such patients may benefit from a more
conservative radiosurgery approach with lower doses
[36,37] or tighter margins.[38]
Thoracic surgery uniformly results in permanent chest
wall scarring and acute pain, which may persist. Nonethe-
less, it remains the standard treatment for stage I NSCLC.
In contrast, carefully designed early stage lung cancer radi-
osurgery may result in only trivial radiation skin reactions
and transient, mild to moderate chest wall pain. The use
of hundreds of lightly weighted beams in this study rather
than a few heavily weighted ones has prevented the infre-
quent but potentially severe skin injuries reported in prior
thoracic radiosurgery series conducted using other radio-
surgical instruments.[12,39] However, mild-to-moderate
chest wall pain, typically lasting several weeks, was seen
following treatment in the majority of patients with
lesions within 5 mm of the pleura. Limiting the dose to
the chest wall would likely diminish the severity of this
complication; however, this may have led to potentially
life threatening local failures and therefore is not recom-
mended at this time given the acceptable and transient
nature of the toxicity observed to date.
The current study required CT-guided fiducial implanta-
tion prior to treatment. This procedure frequently results
in pneumothorax in high-risk patients, often necessitating
tube thoracostomy and a short hospital stay.[37] Fortu-
nately, alternative fiducial placement approaches and a
fiducial-free peripheral lung tumor tracking system are
now available. [40-42] Ongoing research will determine
appropriate patient selection for these new approaches
and their efficacy. In the meantime, fiducial tracking and
CT-guided fiducial placement will remain our standard
approach for small, peripheral lung tumors. The risk of
pneumothorax is justified by the optimal intrafraction tar-
geting verification made possible by properly placed fidu-
cials. We have found that frequent intrafraction targeting
verification and continuous tumor tracking with the Syn-
chrony system allows the delivery of adequate dose to the
gross tumor and its microscopic extension while keeping
the volume of healthy lung exposed to radiation at safe
levels. Although there are other ways of dealing with the
problem of treating tumors that move with respiration,
our experience has made us confident of the safety and
accuracy of this approach.
Conclusion
Thoracic radiosurgery is a new treatment option for stage
I NSCLC.[13,24,39] Optimal clinical outcomes will
require proper patient selection and adequate radiation
doses. Inoperable oxygen-independent patients with
small peripheral lung tumors are ideal candidates.[11]
The delivery of hundreds of radiation beams while contin-
uously tracking and compensating for respiratory tumor
motion will ensure that the gross tumor and radial micro-
scopic extension are effectively treated. Our early experi-
ence suggests that radical CyberKnife radiosurgery will
result in durable local control with acceptable toxicity.
However, larger studies with pathologic confirmation of
tumor eradication and ample follow-up are needed to
confirm our preliminary findings. At this time, surgery
remains the standard treatment option for operable
patients with stage I NSCLC.
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